Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.

chapter 1|11 pages

Precision Medicine and Future Therapeutics

chapter 2|17 pages

Classifications and Risk Factors

chapter 3|11 pages

Historical Milestones

entry |1 pages

Biological Milestones

entry |1 pages

The Nineteenth Century

entry |1 pages

The Twentieth Century

entry |1 pages

The Twenty-First Century

entry |1 pages

Therapeutic Milestones

chapter 4|17 pages

Acute Myeloid Leukaemia

chapter 5|13 pages

Acute Lymphoblastic Leukaemia

chapter 6|15 pages

Chronic Myeloid Leukaemia

chapter 7|18 pages

Myeloproliferative and Related Neoplasms

chapter 9|19 pages

Leukaemias of Mature B- and T/NK-Cells

chapter 10|13 pages

Hodgkin Lymphoma

chapter 11|28 pages

Non-Hodgkin Lymphoma

chapter 12|22 pages

Plasma Cell Neoplasms

chapter 13|11 pages

Principal Treatment-Related Side Effects

chapter 14|4 pages

Concluding Thoughts